Scienza e Tecnologia
Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda
The planned acquisition of Adaptate follows Takeda's recently exercised option to acquire another Abingworth portfolio company, GammaDelta Therapeutics ("GammaDelta"), and is intended to further accelerate the development of innovative γδ T cell-based therapies. Combining GammaDelta's cell therapy-based platform and Adaptate's antibody-based γδ T-cell engager platform with Takeda's strong research and development organisation positions Takeda to be at the leading edge in deploying the full potential of γδ T cells in the fight against cancers.
The acquisitions of Adaptate and GammaDelta are expected to be finalised in Q1 of Takeda's fiscal year 2022, pending completion of review under applicable antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.
Abingworth was a founding investor in both GammaDelta in 2017 and Adaptate in 2019, building upon world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer , at King's College London and the Francis Crick Institute and supported by Cancer Research Technology. Abingworth has played a role in the growth and development of both companies since inception, providing funding, strategic guidance and operational support.
:
View the full press release from Takeda at www.takeda.com/newsroom
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 175 life science companies, leading to 46 M &As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London , Menlo Park ( California ), and Boston .
Adaptate Biotherapeutics is an immunotherapy company developing therapeutic antibodies to modulate the activity of gamma delta T cells. Adaptate's targeted approach enables us to harness and amplify the potential of patients' own immune cells in situ.
Adaptate spun-out from GammaDelta Therapeutics in late 2019 and has received investment from Abingworth and Takeda Pharmaceutical Company Limited.
Tim Haines
Chair & Managing Partner
Tel: +44 (0)20 7534 1500
www.abingworth.com
Mark Swallow or Eleanor Perkin , MEDiSTRAVA Consulting
Tel: +44 (0)203 928 6900
Email: abingworth@medistrava.com